Status:
COMPLETED
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Childhood Chronic Myelogenous Leukemia
Childhood Desmoplastic Small Round Cell Tumor
Eligibility:
All Genders
Up to 21 years
Phase:
PHASE1
Brief Summary
This phase I trial is studying the side effects and best dose of tanespimycin in treating young patients with recurrent or refractory leukemia or selected solid tumors. Drugs used in chemotherapy, suc...
Detailed Description
PRIMARY OBJECTIVES: I. Determine the dose-limiting toxicity and maximum tolerated dose (MTD) of 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) in pediatric patients with recurrent or refractory le...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Histologically confirmed diagnosis of 1 of the following malignancies:
- Leukemia
- Lymphoid, myeloid, or mixed lineage
- Relapsed (in second or greater relapse) or refractory disease, confirmed by 1 of the following:
- Bone marrow relapse, defined as either M3 bone marrow (\> 25% blasts in the bone marrow aspirate) OR M2 bone marrow (5-25% blasts in the bone marrow aspirate) at any time after complete remission is attained
- CNS relapse, defined as at least 5 WBC/mL by cytospin of any cerebrospinal fluid (CSF) specimen OR less than 5 WBC/mL by cytospin of 2 consecutive CSF specimens obtained \>= 4 weeks apart and having definitive confirmation that blasts are derived from the original leukemic clone by molecular cytogenetics, multiparameter flow cytometry, or immunostaining of \>= 2 antigens
- Patients with underlying chronic myeloid leukemia must have \> 25% blasts in the bone marrow aspirate
- Patients with M3 bone marrow AND extramedullary sites of disease, other than leptomeningeal disease, are eligible
- Solid tumor
- One of the following tumor types:
- Neuroblastoma
- Ewing's sarcoma
- Osteosarcoma
- Desmoplastic small round cell tumor
- Rhabdomyosarcoma
- Progressed after prior standard therapy OR no effective standard therapy exists
- Measurable or nonmeasurable disease
- No known brain metastases
- No active leptomeningeal leukemia, defined by the following criteria:
- WBC \> 5/mm\^3 in cerebrospinal fluid (CSF)
- Unequivocal confirmation of leukemic blasts in CSF by cell morphology
- No symptomatic CNS disease (e.g., cranial nerve abnormalities) without cytologic abnormality in CSF
- Performance status - Karnofsky 70-100% (for patients \> 10 years of age)
- Performance status - Lansky 70-100% (for patients =\< 10 years of age)
- More than 8 weeks
- Absolute neutrophil count \>= 750/mm\^3
- Platelet count \>= 75,000/mm\^3 (transfusion independent)
- Hemoglobin \>= 8.5 g/dL (transfusion allowed)
- Bilirubin \< 1.5 mg/dL
- ALT and AST =\< 2.5 times upper limit of normal (ULN)
- INR =\< 1.5 times ULN
- Albumin \> 2.0 g/dL
- Creatinine =\< 1.5 times ULN for age
- Creatinine clearance or radioisotope glomerular filtration rate \> 60 mL/min
- Ejection fraction \>= 50%
- Shortening fraction \>= 28%
- QTc \< 450 msec for men (470 msec for women)
- No congenital long QT syndrome
- LVEF \> 40% by MUGA
- No symptomatic congestive heart failure
- No cardiac arrhythmia
- No New York Heart Association class III or IV heart failure
- No myocardial infarction within the past year
- No uncontrolled dysrhythmias
- No poorly controlled angina
- More than 12 months since active ischemic heart disease
- No history of serious ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation \>= 3 beats in a row)
- No left bundle branch block
- No other significant cardiac disease
- No pulmonary fibrosis by radiography
- No ongoing or active bacterial or fungal infection
- No other uncontrolled illness
- No psychiatric illness or social situation that would preclude study compliance
- No history of serious allergic reaction attributed to eggs or dimethyl sulfoxide
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Recovered from all immunotherapy
- At least 6 months since prior allogeneic stem cell transplantation
- At least 3 months since prior autologous stem cell transplantation
- At least 2 weeks since prior biologic agents (e.g., monoclonal antibodies)
- At least 1 week since prior filgrastim (G-CSF) or sargramostim (GM-CSF)
- Recovered from all prior chemotherapy
- At least 2 weeks since prior chemotherapy (for patients with leukemia only)
- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) (for patients with solid tumors)
- No prior oxaliplatin
- No concurrent corticosteroids except for the treatment of adrenal crises in patients with suppressed hypothalamic-pituitary-adrenal axis response OR for treatment of allergic reactions to medications or blood products
- Recovered from all prior radiotherapy
- At least 6 months since prior radiotherapy to \>= 50% of the pelvis
- At least 6 months since prior radiotherapy to substantial bone marrow, including total body irradiation
- At least 4 weeks since prior local (small port) radiotherapy
- No prior radiotherapy to the heart
- At least 1 week since prior retinoids
- No concurrent antiretroviral therapy for HIV-positive patients
- No concurrent medication to control arrhythmias
- No concurrent medications that prolong or may prolong QTc interval
- No other concurrent investigational agents
- No other concurrent anticancer therapy
Exclusion
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00093821
Start Date
September 1 2004
Last Update
June 4 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065